- Home
- GERN vs ARHS Comparison
GERN vs ARHS Comparison
Compare GERN & ARHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GERN | ARHS |
|---|---|---|
| Founded | 1990 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 956.8M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GERN | ARHS |
|---|---|---|
| Price | $0.99 | $14.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 15 |
| Target Price | $3.63 | ★ $11.38 |
| AVG Volume (30 Days) | ★ 13.5M | 1.8M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 2.71% |
| EPS Growth | ★ 51.85 | N/A |
| EPS | N/A | ★ 0.35 |
| Revenue | $1,065,000.00 | ★ $1,379,222,000.00 |
| Revenue This Year | $27.99 | $5.98 |
| Revenue Next Year | $44.91 | $6.68 |
| P/E Ratio | ★ N/A | $37.57 |
| Revenue Growth | N/A | ★ 8.51 |
| 52 Week Low | $0.84 | $5.57 |
| 52 Week High | $2.01 | $13.23 |
Technical Indicators
Market Signals| Indicator | GERN | ARHS |
|---|---|---|
| Relative Strength Index (RSI) | 42.18 | 74.52 |
| Support Level | $0.84 | $7.23 |
| Resistance Level | $1.67 | N/A |
| Average True Range (ATR) | 0.09 | 0.67 |
| MACD | -0.00 | 0.16 |
| Stochastic Oscillator | 42.50 | 93.89 |
Price Performance
Historical ComparisonAbout GERN Geron Corporation
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
About ARHS Arhaus Inc.
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.